secwatch.observer — SEC 8-K summary
======================================

Issuer:     CEL SCI CORP (CVM)
CIK:        0000725363
Form:       8-K
Filed at:   2025-08-25T23:59:59+00:00
Accession:  0001654954-25-009966
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CEL-SCI files Breakthrough Medicine Designation with Saudi FDA for Multikine; signs MOU with Dallah Pharma
--------------------------------------------------------------------------------

- Breakthrough Medicine Designation application filed with SFDA by Dallah Pharma for Multikine.
- MOU signed with Dallah Pharma for commercialization; final partnership expected Q3 2025.
- SFDA response time ~60 days; if granted, Multikine available for patient access and reimbursement in Saudi Arabia.
- Dallah Healthcare serves over 3 million patients annually via network of hospitals and clinics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/725363/000165495425009966/0001654954-25-009966-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/725363/000165495425009966/cvm_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-25-009966

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer